Profusa Registers $22.2M in Convertible Note Shares for Resale by Selling Stockholder
Summary
Profusa, Inc. filed a prospectus supplement for the resale of up to 2,962,962 shares of common stock by Ascent Partners Fund LLC, stemming from convertible notes with an aggregate principal value of $22.2 million, with the company receiving no proceeds.
Key Events
-
Massive Share Resale Registered
Up to 2,962,962 shares of common stock, convertible from $22.2 million in promissory notes, are registered for resale by Ascent Partners Fund LLC.
-
No Proceeds to Company
Profusa, Inc. will not receive any funds from the sale of these shares by the selling stockholder.
-
Significant Market Overhang
The potential resale represents a substantial portion of the company's market capitalization, creating significant dilutive pressure.
-
Follows Reverse Stock Split
This registration occurs just after the company's 1-for-75 reverse stock split, effective February 9, 2026, and amidst ongoing Nasdaq listing compliance issues.
Analysis
This prospectus supplement registers a substantial amount of common stock for resale by a selling stockholder, stemming from convertible notes with an aggregate principal value of $22.2 million. Profusa, Inc. will not receive any proceeds from these sales, meaning this capital raise does not provide direct funding for operations. The registration of such a large block of shares for resale, equivalent to several times the current market capitalization, introduces considerable dilutive pressure and raises concerns about the company's ability to maintain its listing and financial stability. This event follows closely after the company's 1-for-75 reverse stock split on February 9, 2026, and prior disclosures of Nasdaq delisting notices for minimum bid price and market value of listed securities, intensifying the challenges faced by the company.
At the time of this filing, PFSA was trading at $3.05 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $2.90 to $975.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.